LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR
LGC Drug Development Solutions
LGC’s Drug Development Solutions (DDS) Business Unit is a leading European contract research organization (CRO) that helps clients accelerate, enhance and achieve their product and drug development goals. It has one of the largest concentrations of analytical scientists and experts in Europe with over 275 scientists split between two UK state-of-the-art facilities, in Cambridge and Sandwich, Kent.
DDS’ laboratory services covers all stages of the drug development pipeline from discovery through pre-clinical and clinical development to commercial manufacture of medicines and consumer products. The company offers unrivalled breadth and depth in bioanalysis and analytical and materials science.
Lincoln International ran a tightly run auction process focused on strategic acquirers and designed to minimize disruption. In a highly competitive process, Alliance Pharma, Inc., a US based CRO emerged as a compelling partner for the business and an attractive long term owner. DDS will form an important part of the wider Alliance Pharma, Inc. business as it builds a truly global platform.
Edward Lethbridge, Managing Director and head of Lincoln’s UK Business Services Group, commented, “The CRO and broader pharmaceutical services sector is rapidly growing with DDS representing an exciting prospect as one of the world’s largest single-site bioanalytical solutions laboratories. We are pleased to have advised LGC on their divestment and look forward to watching Alliance Pharma, Inc. continue DDS’ growth in the coming years.”
James West, Director in Lincoln’s Healthcare Group, commented, “LGC’s DDS business is European based provider of Bioanalytical and Analytical and Materials Science Solutions to pharma, biopharma, consumer healthcare and consumer products clients, and it is a natural fit with Alliance Pharma, Inc. to broaden their geographic coverage. The specific bioanalysis services across the pre-clinical and clinical phases are critical for the smooth delivery of clinical trials.”
Meet our Senior Team
View More Transactions in Business Services & Healthcare
Lincoln International advised Proclinic Group, a portfolio company of Miura Partners, on the acquisition of Meditrans
Lincoln International advised Frazier Lifesciences Acquisition Corporation on merger with NewAmsterdam Pharma Holding
Lincoln International advised Müller Transporte on its agreement to sell 70% to Cube Infrastructure Managers
Lincoln International advised Pfingsten Partners on the sale of Full Spectrum Group to CBRE Group
Lincoln International advised Rarebreed, a portfolio company of Trilantic Capital Partners and Halle Capital Management, on receiving significant investment from Revelstoke Capital Partners
Lincoln International advised Corus a portfolio company of Careventures and Quadrum Capital on the refinancing and acquisition of Nordentic
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.